Effect of LY2189265 on the Pharmacokinetics of Atorvastatin in Healthy Subjects.

Trial Profile

Effect of LY2189265 on the Pharmacokinetics of Atorvastatin in Healthy Subjects.

Phase of Trial: Phase I

Latest Information Update: 29 Mar 2017

At a glance

  • Drugs Dulaglutide (Primary) ; Atorvastatin
  • Indications Atrial fibrillation; Cardiovascular disorders; Diabetic foot ulcer; Heart failure; Hypercholesterolaemia; Hyperlipoproteinaemia type II; Hyperlipoproteinaemia type III; Hypertriglyceridaemia; Low HDL cholesterol; Neurological disorders; Retinal vascular occlusion; Systemic lupus erythematosus; Type 2 diabetes mellitus
  • Focus Pharmacokinetics
  • Sponsors Eli Lilly
  • Most Recent Events

    • 29 Mar 2017 Results of pooled analysis from four trials (NCT01458210, NCT01436201, NCT01432938, and NCT01250834) assessing the effect of dulaglutide on PK of digoxin, warfarin, atorvastatin and Ortho-Cyclen and PD of warfarin, published in the Clinical Pharmacokinetics
    • 11 Mar 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 22 Feb 2011 Planned End Date changed from 1 Apr 2011 to 1 Mar 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top